Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Sagres Discovery to Access Celera Discovery System

Rockville, MD and Davis, CA - October 01, 2001

Celera Genomics (NYSE:CRA), an Applera Corporation business, and Sagres Discovery, a functional genomics biotechnology company, announced today that Sagres has signed a multi-year subscription agreement with Celera. Sagres scientists will access the Celera Discovery System™ (CDS) to use Celera's database products, bioinformatics systems, and other discovery tools. Financial terms of the agreement were not disclosed.

“Genomic data and the tools with which to mine and interpret this data are crucial components of research programs today,” said J. Craig Venter, Ph.D., Celera's president and chief scientific officer. “We are pleased that Sagres Discovery has chosen to utilize the comparative genomics capabilities and powerful bioinformatics tools that the Celera Discovery System offers. We believe CDS should help them in their efforts to uncover new treatments against cancer.”

“Having access to the Celera database dramatically accelerates our discovery process,” said Marc Malandro, Ph.D., Sagres Discovery’s Vice President of High Throughput Biology. “This agreement should have a major impact on our efforts to understand the molecular basis of cancer.”

The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, and genomic and biological data to advance the discovery process for researchers worldwide.

About Sagres Discovery
Sagres Discovery is a biotechnology company with an established market position in oncology. The company has pioneered methods to rapidly identify and validate disease-causing cancer genes for use in the development of new cancer diagnostics and therapeutics. Sagres’ comprehensive target identification platform facilitates efficient and cost-effective discovery and development of small molecule compounds and therapeutic antibodies that act against novel drug targets. In the post-genomics era, Sagres Discovery is well positioned to produce the next generation of targeted cancer therapeutics. Sagres Discovery is based in Davis, CA. For more information, visit

About Celera
Applera Corporation comprises two operating groups. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation diagnostic and therapeutic discovery business. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for subscribers and for its own internal product development. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at, or by telephoning 800.762.6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” and “potential,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks factors include but are not limited to (1) a unique and expanding business plan; (2) uncertainty of revenue growth; (3) dependence on the continued assembly and annotation of the human and other genomes; (4) unproven use of genomic information to develop or commercialize products; (5) uncertainty and availability of patent, copyright, and intellectual property protection and the ability to protect trade secrets; (6) dependence on computer hardware, software, and internet applications; (7) legal, ethical, and social issues affecting demand for products; (8) disruptions caused by rapid growth of the business; (9) government regulation of its products and services; (10) potential adverse effect on the Celera Genomics Group’s intellectual property protection and the value of its products and services due to public disclosure of genomic sequence data; (11) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.